ATAC21

A recombinant bispecific antibody, comprises: a) a target antigen binding domain, wherein the target antigen binding domain specifically binds to a tumor associated antigen; b) an effector antigen binding domain, wherein the effector antigen binding domain specifically binds to an antigen on an antigen presenting cell and wherein the antigen is a molecule on the antigen presenting cell; c) an Fc comprising domain; and d) an immune- stimulatory compound attached to the recombinant bispecific antibody by a linker; wherein the recombinant bispecific antibody induces greater immune cell activation when the recombinant bispecific antibody is bound to the tumor associated antigen and to the antigen on the antigen presenting cell as compared to when the recombinant bispecific antibody is bound to the antigen on the antigen presenting cell but not to the tumor associated antigen^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.